Actinogen Medical Limited Appoints Avance Clinical and Paratus Clinical to Assist in the Conduct, Management, and Recruitment of the Xanamia Part A Dose Ranging Study
June 20, 2021 at 07:30 pm EDT
Share
Actinogen Medical (ACW or the Company) announced that it has appointed Avance Clinical (Avance) and Paratus Clinical (Paratus) to assist in the conduct, management, and recruitment of the XanaMIA Part A dose ranging study. Further, the Company has finalised its agreement with Australian neuroscience technology company Cogstate, to utilise its Neuropsychological Test Battery in the XanaMIA study. The XanaMIA Part A study is to be conducted at four Paratus clinics in Australia and will enroll a total of 105 healthy volunteers aged 50 years and over in a dose ranging study of 5mg and 10mg Xanamem® doses, to confirm the minimum effective dose. The total work order with Avance will be AUD 1.25 million. Paratus, a provider of a clinical-trial site network and related services across Australia, will perform all subject recruitment activities, with a total budget of AUD 850,000. Actinogen finalised a work order with Cogstate in April for USD 300,000, to utilise its Neuropsychological Test Battery, a modern platform designed to deliver highly sensitive cognition tests.
Cogstate Ltd is a neuroscience technology company. It is engaged in the creation, validation, and commercialization of digital brain health assessments and design and assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments. Its segments include Clinical Trials, Healthcare, and Research. The Clinical Trials segment includes adoption of decentralized clinical trial methodologies and scientific publication and marketing of the utility and validity of Cogstate technology. The Healthcare segment includes Cognigram, which allows for regular and standardized testing to assist in the early detection of cognitive decline that could be related to a range of factors including head injury, neurodegenerative disease or side effects following pharmacological treatments. The Research segment includes research studies and academic collaborations across various indications, such as Alzheimerâs disease and Parkinsonâs disease.
Actinogen Medical Limited Appoints Avance Clinical and Paratus Clinical to Assist in the Conduct, Management, and Recruitment of the Xanamia Part A Dose Ranging Study
COGSTATE LIMITED 
